One Wealth Advisors LLC Takes $827,000 Position in Edwards Lifesciences Corporation $EW

One Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 9,145 shares of the medical research company’s stock, valued at approximately $827,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Edwards Lifesciences by 27.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after buying an additional 23,514 shares during the last quarter. Norges Bank bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth $803,686,000. TD Asset Management Inc raised its holdings in Edwards Lifesciences by 6.4% in the fourth quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after acquiring an additional 47,051 shares in the last quarter. Intech Investment Management LLC raised its holdings in Edwards Lifesciences by 22.2% in the fourth quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company’s stock valued at $5,912,000 after acquiring an additional 12,591 shares in the last quarter. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Edwards Lifesciences in the fourth quarter valued at $1,626,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 1.1%

NYSE EW opened at $91.51 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company has a 50-day simple moving average of $88.73 and a 200-day simple moving average of $84.37. The firm has a market capitalization of $52.69 billion, a PE ratio of 52.59, a price-to-earnings-growth ratio of 2.30 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the prior year, the business earned $0.67 earnings per share. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

EW has been the subject of several recent analyst reports. Truist Financial raised their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Barclays reaffirmed an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Finally, Mizuho increased their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Insider Activity

In other news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 26,190 shares of company stock valued at $2,269,697. 0.31% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.